评估68Ga-FAPI PET/CT在胃黏液腺癌或印戒细胞癌中的价值
前瞻性纳入86例新诊断或复发性胃黏液腺癌或印戒细胞癌患者,均行18F-FDG PET/CT和68Ga-FAPI PET/CT。68Ga-FAPI PET/CT在检出受累淋巴结和腹膜转移方面的诊断准确性更高,30%的患者因更准确的诊断而改变了治疗策略,且68Ga-FAPI PCI是PFS的独立预测因素。
要点
- 68Ga-FAPI PET/CT检出受累淋巴结的准确性为87%(212/244),高于18F-FDG PET/CT的71%(173/244)。
- 68Ga-FAPI PET/CT检出腹膜转移的准确性为96%(70/73),高于18F-FDG PET/CT的55%(40/73)。
- 30%(26/86)的患者因68Ga-FAPI PET/CT更准确的诊断而改变了治疗策略。
核心结论
- 68Ga-FAPI PET/CT诊断胃黏液腺癌或印戒细胞癌的准确性高于18F-FDG PET/CT,并显示出改善治疗策略和预测预后的潜力。
研究设计与样本
- 前瞻性研究,纳入86例新诊断或复发性胃黏液腺癌或印戒细胞癌患者,均行18F-FDG PET/CT和68Ga-FAPI PET/CT,记录治疗策略变化,并进行生存分析。
诊断标准与关键数值
- 68Ga-FAPI PET/CT检出受累淋巴结的准确性为87%(212/244),18F-FDG PET/CT为71%(173/244),P < .001。
- 68Ga-FAPI PET/CT检出腹膜转移的准确性为96%(70/73),18F-FDG PET/CT为55%(40/73),P < .001。
- 68Ga-FAPI PCI是PFS的独立预测因素(HR 6.9,95% CI:2.1,23.1,P = .002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate the clinical impact and prognostic value of gallium 68 (68Ga)-labeled fibroblast activation protein inhibitor (FAPI) PET/CT in gastric mucinous adenocarcinoma (MAC) and signet ring cell carcinoma (SRCC). Materials and Methods Eighty-six participants with newly diagnosed or recurrent gastric MAC or SRCC were prospectively enrolled from April 2021 to October 2021 and underwent both fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT and 68Ga-FAPI PET/CT. The sensitivity, specificity, and accuracy of the two scans in primary and metastatic tumors were evaluated using the McNemar test. Changes of treatment strategies were recorded to compare the treatment management value of the two PET/CT scans. The maximum standardized uptake value (SUVmax) and peritoneal cancer index (PCI) were recorded for survival analysis. Progression-free survival (PFS) was defined as the time interval from the date of PET/CT scans to the date of disease progression. Results Eighty-six participants (median age, 62 years [IQR, 45-78 years]; 49 female) were evaluated. 68Ga-FAPI PET/CT showed higher diagnostic accuracy in detecting involved lymph nodes (87% [212 of 244] vs 71% [173 of 244], P < .001) and peritoneal metastases (96% [70 of 73] vs 55% [40 of 73], P < .001) than 18F-FDG PET/CT. Twenty-six participants (30% [26 of 86]) had treatment changes due to more accurate diagnosis with 68Ga-FAPI PET/CT. Additionally, the 68Ga-FAPI PCI was an independent predictor for PFS (hazard ratio, 6.9; 95% CI: 2.1, 23.1; P = .002). Conclusion 68Ga-FAPI PET/CT had higher accuracy in diagnosis of gastric MAC/SRCC compared with 18F-FDG PET/CT and demonstrated the potential to improve treatment strategies and predict prognosis. Keywords: PET/CT, Mucinous Adenocarcinoma, Signet Ring Cell Carcinoma, Oncology, Abdomen/GI, Molecular Imaging Supplemental material is available for this article. © RSNA, 2024.
引用
- Sun Y, Xu J, Qiao Y, et al. Assessing the Value of 68Ga-FAPI PET/CT in Gastric Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma. Radiol Imaging Cancer. 2024. PMID: 39422573. doi:10.1148/rycan.230195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。